PRL offers good results for high myopia

Article

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia.

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia, according to Esther Arranz-Marquez and co-workers from Vissum Corporación Oftalmológica de Madrid, Spain.

In a prospective study, the PRL was implanted in 78 myopic eyes in which the refractive error ranged between -4.0 and -31.0 D and laser refractive surgery was contraindicated. Uncorrected and best corrected visual acuity (UCVA & BCVA), manifest and cycloplegic refractions and intraocular pressure (IOP) were assessed over a three-year follow-up period.

The results revealed a significant change in spherical equivalent from a preoperative mean value of -14.7±5.4 D to 0±0.8 D three years postoperatively (p<0.01). UCVA and BCVA also improved significantly (p<0.01). Although a significant increase in IOP was found at each postoperative visit (p<0.01), there was no significant difference in IOP between one and three years postoperatively. Four eyes were operated on again due to mild lens decentration.

It was concluded that implantation of a PRL can offer good and predictable results for the correction of high myopia.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.